[Retracted] Prognostic Factors of IIIAN2 Non-Small-Cell Lung Cancer after Complete Resection: A Systemic Review and Meta-analysis

Table 1

Overview of selected studies.

S. no	Author’s name, year, and reference	Location	Study design	No. of patients	Duration	Study center	Prognostic factors	Survival rate (1 LN)
1	Mountain, 1994 [5]	Houston, Texas	Retrospective data review	1,017	1983-1988	University of Texas M. D. Anderson Cancer Center	Complete dissection of lymph node; Complete tumor resection; Number and level of lymph nodes involved; Tumor status	5-year survival rate (1LN): 37%; 5-year survival rate (2-4 LN): 27%; 5-year survival rate (>4 LN): 17%
				1,866	1977-88	National Cancer Institute Cooperative Lung Cancer Study Group
2	Vansteenkiste et al., 1997 [13]	China	Retrospective data review	140	1985-1993	University Hospital Gasthuisberg, Catholic University Leuven	Complete tumor resection; Performance status; Histology analysis; cN2	20.8%; Mediastinoscopy-negative patients: 32.2%
3	Tanaka et al., 2004 [14]	Japan	Retrospective data review	99	—	Faculty of Medicine, Kyoto University	Number of LN involved; LN stations; LN status; Proliferative index	5-year survival rate (1LN): 41.6%; 5-year survival rate (2-4 LN): 35.3%; 5-year survival rate (>4 LN): 0.0%
4	Barlési et al., 2005 [9]	France	Retrospective data review	95	1993-2003	Hospital Sainte Marguerite	LN clearance status; Postoperative issues; Selection of surgical strategy; Complete tumor resection; Blood and pleural invasion; Downstaging	Survival rate: 20 vs. 16 months
5	Betticher et al., 2006 [15]	Switzerland	Trial	75	—	Clinic of Medical Oncology, Hospital of Fribourg	Complete tumor resection pathological response downstaging	OS: 35 months; EFS: 15 months
6	Garrido et al., 2007 [16]	Spain	Trial	62	December 1999 to March 2003	Hospital Ramon y Cajal	Complete tumor resection; Clinical response; years	Complete resection; 3-year survival rate: 60.1%; 5-year survival rate: 41.4%; Incomplete resection; 3-year survival rate: 23.1%; 5-year survival rate: 11.5%; Nonresected cases; 3-year survival rate: 31.1%; 5-year survival rate: 0%
7	Kim et al., 2007 [17]	Republic of Korea	Study report	66	—	Sungkyunkwan University School of Medicine	ypN0 stage	5 years; OS: 27%; DFS: 24%; Local control rates: 90%
8	Kim et al., 2008 [18]	Republic of Korea	Study report	42	January 2001 to January 2006	Yonsei University College of Medicine	Downstaging	2 years; DFS (without LN metastasis): 46%; DFS (with LN metastasis): 18%
9	Lee et al., 2008 [19]	Republic of Korea	Retrospective data review	262	1990-2005	Yonsei University College of Medicine	LN stations; Age; Secondary CT	5-year survival rate (1LN): 33.8%; 5-year survival rate (multiple LN): 20.4%
10	Albain et al., 2009 [20]	USA	Phase II trial	202	—	Loyola University Chicago Stritch School of Medicine	LN stations; Gender; Weight reduction	Median OS: 23.6 months
11	Liu et al., 2012 [21]	China	Retrospective data review	63	2004-2008	Peking University First Hospital	LN stations; Number and position of involved LNs	2-year recurrence rate: 46.6%; 3-year recurrence rate: 57.3%
12	Liu et al., 2013 [22]	China	Retrospective data review	89	2003 to April 2007	Peking University First Hospital	T3 stage; LN invasion; LN stations; years; Number and position of involved LNs; >3 involved LN refer to worse prognosis	3-year survival rate: 51.7%; 5-year survival rate: 31.5%
13	Qiang et al., 2014 [23]	China	Retrospective data review	92	—	China-Japan Friendship Hospital	Number and location of involved LNs; Subgrouping of MLN; >3 involved LN refer to worse prognosis	3-year recurrence rate: 61.0%; 5-year recurrence rate: 70.2%
14	Yoo et al., 2015 [24]	Seoul, Korea	Retrospective data review	206	1997 to 2004	University of Ulsan College of Medicine	Number of metastatic LNs	5-year OS: 37.7%
15	Chen et al., 2020 [10]	Taiwan	Retrospective data review	77	2006 and 2014	China Medical University Hospital	<3 cm of tumor LN and VATS approach	1-year survival: 91.9%; 3-year survival: 61.3%; 5-year survival: 33.5%

LVI: lymphatic or vascular invasion; CT: chemotherapy; VATS: video-assisted thoracoscopic surgery; DFS: disease-free survival; OS: overall survival; EFS: event-free survival.